RxDoctor Payments Data

Nicole Domenech, MD

General Practice · San Juan, PRNPI 1518336825

Payments from drug & device makers

$518in general payments, 2019–2025

Across 31 payments — averaging $16.70 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$99
  • Vanda Pharmaceuticals Inc.$75
  • AstraZeneca$69
  • Bayer$47
  • Biohaven Pharmaceutical Holding Company Ltd.$34
  • Lilly USA, LLC$30
  • plus $164 from 10 others

What the payments were for

  • Food & beverage$49496%
  • Education$234%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$518 in reported general payments places this provider in the 75th percentile of 3,586 general practice providers in Puerto Rico.

See all general practice providers in Puerto Rico

Medicare billing

Part B allowed, 2024
$14,868
Medicare patients
47
Services billed
248

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide80$126,454
EliquisApixaban73$105,289
JardianceEmpagliflozin66$87,284
TrulicityDulaglutide40$66,038
FarxigaDapagliflozin Propanediol47$65,082
MounjaroTirzepatide34$48,845
JanuviaSitagliptin Phosphate36$47,825
EntrestoSacubitril/Valsartan19$36,710
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$19,534
XareltoRivaroxaban22$17,809
SymbicortBudesonide/Formoterol Fumarate31$15,791
TradjentaLinagliptin13$13,103
Tresiba Flextouch U-100Insulin Degludec15$10,767
Lantus SolostarInsulin Glargine,hum.Rec.Anlog43$5,917
LantusInsulin Glargine,hum.Rec.Anlog30$5,909

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Levemir$99$129,05393 claims
Lilly USA, LLCTrulicity, Mounjaro$30$114,88374 claims
AstraZenecaFarxiga, Symbicort$69$80,87378 claims
GSKTrelegy Ellipta$13$19,53415 claims
Johnson & JohnsonXarelto$15$17,80922 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 3,586 general practice providers in Puerto Rico.

Other general practice in San Juan

See the full list for Puerto Rico

Where these figures come from

Is this you, or does something look wrong? →